Results 121 to 130 of about 4,821 (183)

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial [PDF]

, 2016
Abhishek Mishra, Bruce W. Bode, Jean-Pierre Courrèges, Louis B. Chaykin, Lucine M. Lehmann, Richard W. Simpson, Sultan Linjawi, Yehuda Handelsman   +7 more
core   +1 more source

Research progress in precision medicine for type 2 diabetes based on the GLP-1. [PDF]

Front Endocrinol (Lausanne)
Wang S, Yuan C, Wang H, Ye X, Ruan S, Yi L, Yang W, Wang Z, Wang N, Li J, Feng X, Li Y, Tian Y, Wang Q.   +13 more
europepmc   +1 more source

Neuroendocrinology meets addiction: Emerging pharmacotherapies on the horizon. [PDF]

J Intern Med
Loften A, Farokhnia M, Vendruscolo LF, Leggio L.   +3 more
europepmc   +1 more source

The effect of a Dual Amylin and Calcitonin Receptor Agonist (DACRA) on adipose tissue and energy expenditure [PDF]

, 2023
openaire  

The Voice of a Disease: Why Food Noise Can No Longer Be Ignored! [PDF]

Obesity (Silver Spring)
Alhazmi A, le Roux CW.
europepmc   +1 more source

Liver-pancreas communication in disease and drug development. [PDF]

Acta Pharm Sin B
Jia Y, Zhu Q, Pan Q, Lu G, Xiao J.
europepmc   +1 more source

GLP-1-based therapeutics for cardiorenal protection in metabolic diseases. [PDF]

Nephrol Dial Transplant
Apperloo EM, Heerspink HJL, van Raalte DH, Muskiet MHA.   +3 more
europepmc   +1 more source

Discovery of peptides as key regulators of metabolic and cardiovascular crosstalk. [PDF]

Cell Rep
Zhang Z, Svensson KJ.
europepmc   +1 more source

The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. [PDF]

EBioMedicine
Kuhre RE, Ballarín-González B, Brand CL, Glendorf T, Madsen KG, Hjøllund KR, Hogendorf WFJ, Ipsen DH, Lundh S, Kruse T, Petersen SB, Secher A, Vegge A, Raun K.   +13 more
europepmc   +1 more source